Coronavirus: Prescription Drugs

Department of Health and Social Care written question – answered at on 4 April 2022.

Alert me about debates like this

Photo of Baroness Rawlings Baroness Rawlings Conservative

To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 28 March (HL7225), why decisions on the deployment of antiviral treatments for COVID-19 for people beyond the highest risk groups are tied to the outcomes of the PANORAMIC study; and when they expect such decisions to be made.

Photo of Lord Kamall Lord Kamall The Parliamentary Under-Secretary for Health and Social Care

We are ensuring that deployment of antiviral treatments is supported by comprehensive data on clinical and cost-effectiveness to ensure healthcare professionals and patients have full confidence in prescribing and receiving these treatments.

The PANORAMIC study was established following a recommendation from an expert clinical panel. The expert panel advised that additional information should be gathered on which patients would benefit most from antiviral treatments in the United Kingdom, given high rates of vaccination. Previous trials have predominantly used unvaccinated participants.

Results for the first antiviral treatment, molnupiravir, are likely to be available in summer 2022, when a decision on clinical access will be made by an expert panel. The second antiviral treatment, Paxlovid, is expected to enter the PANORAMIC study in April 2022.

Does this answer the above question?

Yes2 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.